NI201700158A - FRAGMENTED INACTIVATED FLU VACCINE AND THE METHOD OF ITS OBTAINMENT. - Google Patents
FRAGMENTED INACTIVATED FLU VACCINE AND THE METHOD OF ITS OBTAINMENT.Info
- Publication number
- NI201700158A NI201700158A NI201700158A NI201700158A NI201700158A NI 201700158 A NI201700158 A NI 201700158A NI 201700158 A NI201700158 A NI 201700158A NI 201700158 A NI201700158 A NI 201700158A NI 201700158 A NI201700158 A NI 201700158A
- Authority
- NI
- Nicaragua
- Prior art keywords
- carried out
- allantoic fluid
- influenza
- infected
- infected allantoic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Virology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invención se refiere a Inmunología, medicina, farmacología y se relaciona con la producción de vacunas antigripales inactivadas, las cuales pueden ser utilizadas para la vacunación de la población de Rusia contra la gripe. Método para la obtención de un medio destinado a la curación de la gripe que incluye la infección de embriones de pollo con el virus de la gripe, la incubación de los embriones infectados, la refrigeración de los embriones incubados, la recogida del fluido alantoideo infectado, el procesado del fluido alantoideo infectado con el objetivo de su desagregación e inactivación, la microfiltración del fluido alantoideo infectado en 2 cascadas de cartuchos, la ultrafiltración del fluido alantoideo infectado y la purificación del concentrado viral en el gradiente de la densidad de la sacarosa. La fragmentación del concentrado viral purificado e inactivado se lleva a cabo con detergente beta-octilglucósido, la eliminación de los viriones sin destruir completamente y los complejos de ribonucleoproteidos con proteínas membranosas se realiza con el método de ultracentrifugación, la purificación final de los antígenos separados se realizará en un medio cromatográfico después de lo cual a los antígenos obtenidos se le añadirá un estabilizador. Se diferencia en que la inactivación de la actividad del virus, la realizamos en la fase de procesado del fluido alantoideo infectado con la utilización de desinfectante beta-propiolactona, la desagregación de los virus durante el procesado del fluido alantoideo infectado la realizamos con cloruro de sodio en una concentración final, y la purificación final de los antígenos la realizamos en el medio cromatográfico WorkBeads 40/100/sec de la empresa BioWorks (Suecia), y la estabilización usando detergente Triton X-100 en una concentración de 100-300 ?g/ml. También se propone un fármaco para tratar la influenza, que se produce por el método mencionado anteriormente.The invention relates to Immunology, medicine, pharmacology and relates to the production of inactivated influenza vaccines, which can be used for the vaccination of the Russian population against influenza. Method for obtaining a medium for the cure of influenza that includes the infection of chicken embryos with the influenza virus, the incubation of the infected embryos, the refrigeration of the incubated embryos, the collection of the infected allantoic fluid, the processing of the infected allantoic fluid with the objective of its disaggregation and inactivation, the microfiltration of the infected allantoic fluid in 2 cascades of cartridges, the ultrafiltration of the infected allantoic fluid and the purification of the viral concentrate in the sucrose density gradient. The fragmentation of the purified and inactivated viral concentrate is carried out with beta-octylglucoside detergent, the elimination of the virions without completely destroying and the complexes of ribonucleoproteides with membranous proteins is carried out with the ultracentrifugation method, the final purification of the separated antigens is It will be carried out in a chromatographic medium after which a stabilizer will be added to the antigens obtained. It differs in that the inactivation of the virus activity is carried out in the processing phase of the infected allantoic fluid with the use of beta-Propiolactone disinfectant, the disaggregation of the viruses during the processing of the infected allantoic fluid is carried out with sodium chloride in a final concentration, and the final purification of the antigens was carried out in the chromatographic medium WorkBeads 40/100 / sec from BioWorks (Sweden), and stabilization using Triton X-100 detergent at a concentration of 100-300? g / ml. A drug is also proposed to treat influenza, which is produced by the method mentioned above.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2015126582/15A RU2584594C1 (en) | 2015-07-02 | 2015-07-02 | Inactivated split influenza vaccine and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201700158A true NI201700158A (en) | 2018-04-10 |
Family
ID=56012209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201700158A NI201700158A (en) | 2015-07-02 | 2017-12-14 | FRAGMENTED INACTIVATED FLU VACCINE AND THE METHOD OF ITS OBTAINMENT. |
Country Status (3)
| Country | Link |
|---|---|
| NI (1) | NI201700158A (en) |
| RU (1) | RU2584594C1 (en) |
| WO (1) | WO2017003322A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2710239C1 (en) * | 2019-06-14 | 2019-12-25 | Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства | Method of producing antigen or antigens for production of influenza vaccine and a vaccine based on it |
| RU2740751C1 (en) * | 2019-08-28 | 2021-01-20 | Общество с ограниченной ответственностью "Развитие БиоТехнологий" | Method of producing tetravalent subunit influenza vaccine |
| RU2741003C1 (en) * | 2020-03-27 | 2021-01-22 | Евгений Дмитриевич Некрасов | Method for production of tetravalent subunit vaccine against influenza without adjuvants |
| RU2754398C1 (en) * | 2020-06-25 | 2021-09-01 | Общество с ограниченной ответственностью «ФОРТ» | Method for obtaining a tetravalent vaccine for the prevention of influenza |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102600468A (en) * | 2012-03-01 | 2012-07-25 | 浙江天元生物药业有限公司 | Preparation process of avian influenza virus split vaccine containing MF59 adjuvant |
| RU2523614C1 (en) * | 2013-04-09 | 2014-07-20 | Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации | Vaccine against influenza and method for its preparation |
-
2015
- 2015-07-02 RU RU2015126582/15A patent/RU2584594C1/en active
-
2016
- 2016-07-04 WO PCT/RU2016/000413 patent/WO2017003322A1/en active Application Filing
-
2017
- 2017-12-14 NI NI201700158A patent/NI201700158A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017003322A1 (en) | 2017-01-05 |
| RU2584594C1 (en) | 2016-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201700158A (en) | FRAGMENTED INACTIVATED FLU VACCINE AND THE METHOD OF ITS OBTAINMENT. | |
| BR112017014219A2 (en) | multivalent nanoparticle-based vaccines | |
| JP2022066209A (en) | High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs | |
| RU2496519C2 (en) | Method for producing preparation containing viral antigens and using preparation | |
| EA201892034A1 (en) | ELIMINATION OF HEPATITIS B VIRUS WITH THE HELP OF ANTI-VIRUS AGENTS | |
| EA201891000A1 (en) | VACCINE AGAINST RESPIRATORY-SYNCTIAL VIRUS | |
| EA201792429A1 (en) | Derivatives of mono-or dislocated indo as an inhibitor of dengue virus replication | |
| BR112018009032A8 (en) | infectious arenavirus viral vector, pharmaceutical composition, immunogenic composition, vaccine, method for treating or preventing hepatitis b virus infection in a patient, use of a viral vector, isolated nucleic acid, replication-deficient infectious arenavirus viral vector and method for its generation | |
| CY1122792T1 (en) | MONO-OR DISUBTITUTED INDOLE DERIVATIVES AS DANGE VIRUS REPLICATION INHIBITORS | |
| EA201892219A1 (en) | SUBSTITUTED INDIN DERIVATIVES AS AN INHIBITORS OF DENG VIRUS REPLICATION | |
| EA201892200A1 (en) | SUBSTITUTED DERIVATIVE COMPOUNDS OF INDOL AS AN INGIBITORS FOR DENG VIRUS REPLICATION INHIBITORS | |
| EA201892214A1 (en) | SUBSTITUTED DERIVATIVES OF INDOL AS AN INHIBITORS OF DENG VIRUS REPLICATION | |
| BR112016028816A8 (en) | immunogenic combination, method of obtaining a specific immune response, use of an immunogenic combination, and, vaccination regimen for the prevention, reduction or treatment of respiratory syncytial virus infection | |
| EA201892216A1 (en) | SUBSTITUTED INDIN DERIVATIVES AS AN INHIBITORS OF DENG VIRUS REPLICATION | |
| EA201791614A1 (en) | INDOL DERIVATIVES AS AN INHIBITORS OF DENGE VIRUS REPLICATION | |
| EA202091769A1 (en) | VACCINES AGAINST THE INFLUENZA VIRUS AND THE WAYS OF THEIR APPLICATION | |
| PE20170429A1 (en) | VACCINE IN RECOMBINANT VECTOR OF AVIAN ADENOVIRUS SEROTYPE 9 | |
| Boltz et al. | Antiviral activity of enisamium against influenza viruses in differentiated normal human bronchial epithelial cells | |
| EA201400235A1 (en) | VACCINES AGAINST FLU BASED ON H5 | |
| RU2599496C2 (en) | Improved vaccination against influenza | |
| EA201500837A1 (en) | PARABOVIRUS OF PIGS 5B, METHODS OF APPLICATION AND VACCINE | |
| RU2703147C2 (en) | Method of producing vaccine antigens, obtained vaccine antigens and use thereof | |
| BR112020010202A8 (en) | H9 AVIAN INFLUENZA VACCINE STRAIN THAT DIFFERENTIATES INFECTED ANIMALS FROM VACCINATED ANIMALS, AND METHOD OF PREPARATION FOR THE SAME | |
| RU2563352C2 (en) | STRAIN A/17/Texas/2012/30 (H3N2) OF INFLUEZA VIRUS FOR PRODUCING INTRANASAL LIVE INFLUENZA VACCINE FOR ADULTS AND CHILDREN | |
| RU2605314C1 (en) | VACCINE INFLUENZA VIRUS STRAIN A/17/Bolivia/2013/6585 (H1N1)pdm09 FOR PREPARING LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN |